"10.1371_journal.pone.0080132","plos one","2013-11-14T00:00:00Z","Gallen Triana-Baltzer; Adam Pavlicek; Ariadne Goulart; Hanhua Huang; Steven Pirie-Shepherd; Nancy Levin","CovX Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America; Oncology Research Unit, Pfizer Worldwide Research and Development, San Diego, California, United States of America","Conceived and designed the experiments: GTB SPS NL HH. Performed the experiments: AG GTB. Analyzed the data: AP. Contributed reagents/materials/analysis tools: AP. Wrote the manuscript: GTB.","The authors of this manuscript declare their affiliation past or present with the commercial funder of this research Pfizer, Inc. All authors were employees of Pfizer at the time of this work and played roles in study design, data collection and analysis, decision to publish, and preparation of the manuscript. S. Pirie-Shepherd is a current employee of Pfizer, Inc. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. G. Triana-Baltzer, A. Goulart, H. Huang, and N. Levin are employees of CovX Research, Pfizer Worldwide Research Development. S. Pirie-Shephed is an employee of Oncology Research Unit, Pfizer Worldwide Research Development. A. Pavlicek is a former employee of Oncology Research Unit, Pfizer Worldwide Research and Development. The Angiopoietin-2 targeting compound described here, CVX-060, is being developed by Pfizer Inc. The authors of this manuscript were or are employees of Pfizer. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","11","Gallen Triana-Baltzer","GTB",6,TRUE,4,2,1,1,TRUE,FALSE,FALSE,0,NA,FALSE
